Recently, Wondfo Bio and Merck, a leading global technology company, held a globalization cooperation seminar and unanimously decided to deepen the cooperation on the basis of the pilot cooperation in the previous period, expanding the project coverage area and the population, and joining hands to enhance the accessibility of the diagnosis and treatment of thyroid diseases at the grassroots level in the world.

DiaSorin said on Thursday that its second quarter revenues fell around 12 percent year over year on a constant currency basis, as it experienced an expected continued sharp decline in COVID-19 testing, partially offset by improvements in other immunodiagnostics sales.

Excluding COVID-19 products, Group sales increase strongly by 8%1 at constant exchange rates (CER)

On the evening of July 26, Autobio announced that the company participated in the investment in Suzhou JinHe Fund as a limited partner, with a subscription amount of RMB 100 million.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 1, 2023.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.

Quest Diagnostics on Wednesday reported that its second quarter revenues fell 5 percent year over year although its base business revenues increased nearly 10 percent. The company also beat analysts' expectations on the top and bottom lines.

Medical device registration is an essential part of ensuring product safety, effectiveness, and quality. This article will introduce the whole process of medical device registration in detail, including pre-application preparation, registration test, clinical trial, establishment of system, application acceptance, approval of registration, issuance of registration certificate and follow-up supervision.

GE HealthCare raised its profit forecasts for 2023 after recording better-than-expected financials in its Q2 earnings report.

Danaher reported on Tuesday that its second quarter revenues fell approximately 8 percent year over year due to ongoing declines in COVID-related product demand and a drop in biotechnology business revenues.

Chinese IVD instruments market grows from RMB 10.12 billion to RMB 22.32 billion by 2020 from 2016 to 2020, at a CAGR of 21.9%. Stimulated by favorable national policies and the growing demand, it is expected to reach RMB 60.99 billion in 2025 and RMB 114.62 billion in 2030, growing at a CAGR of 22.3% and 13.4% during the periods 2020-2025 and 2025-2030, respectively.

DiaCarta said Monday that it has formed a strategic partnership with New Jersey-based contract research organization Hopkins MedTech Compliance/Hopkins MedTech Lab Services to provide validation and regulatory compliance services for laboratory test and in vitro diagnostic developers in the US.

QuidelOrtho Corporation, a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has entered into a software development partnership with BYG4lab®, a leading provider of middleware and data management solutions for laboratories, that intends to accelerate QuidelOrtho’s efforts to expand and strengthen informatics offerings across its portfolio of diagnostics platforms.

On July 19, 2023, the Third People’s Hospital of Shenzhen (hereinafter referred to as Shenzhen Third Hospital) and Shenzhen New Industries Biomedical Engineering Co., Ltd. (hereinafter referred to as Snibe) successfully held an exchange seminar and a signing ceremony of strategic cooperation on “Industry-University-Research-Hospital-Application”.

Invivoscribe is excited to announce that the LeukoStrat CDx FLT3 Mutation Assay has been approved by the U.S. Food and Drug Administration (FDA) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be eligible to receive treatment with Daiichi Sankyo’s VANFLYTA® (quizartinib).